Algernon Health Inc.

Algernon Health Inc. is a clinical-stage biotechnology company specializing in the development of repurposed therapeutic drugs targeting serious medical conditions such as non-alcoholic steatohepatitis (NASH), chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, stroke, and traumatic brain injury recovery. The company focuses on advancing its lead drug candidates—including NP-251 (Repirinast) and AP-188 (DMT)—through off-label Phase II clinical trials in Canada and Australia. Its subsidiary, Algernon NeuroScience Inc., develops AP-188 as a potential treatment for stroke and brain trauma. Operating within the biotechnology and medical research sector, Algernon Health emphasizes innovative drug repurposing strategies aimed at addressing significant unmet medical needs, contributing to the evolving pharmaceutical pipeline for complex diseases.